{"id":1435,"date":"2026-01-15T13:53:11","date_gmt":"2026-01-15T12:53:11","guid":{"rendered":"https:\/\/adile.es\/?p=1435"},"modified":"2026-01-15T16:33:33","modified_gmt":"2026-01-15T15:33:33","slug":"la-comision-europea-aprueba-un-tratamiento-pata-la-diabetes-tipo-1","status":"publish","type":"post","link":"https:\/\/adile.es\/index.php\/2026\/01\/15\/la-comision-europea-aprueba-un-tratamiento-pata-la-diabetes-tipo-1\/","title":{"rendered":"LA COMISI\u00d3N EUROPEA APRUEBA UN TRATAMIENTO PARA LA DIABETES TIPO 1"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"1435\" class=\"elementor elementor-1435\">\n\t\t\t\t<div class=\"elementor-element elementor-element-950ae9e e-flex e-con-boxed e-con e-parent\" data-id=\"950ae9e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3b67443 elementor-widget elementor-widget-text-editor\" data-id=\"3b67443\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"color: #000000;font-family: Arial, sans-serif;font-size: 15px;text-align: justify\">La Comisi\u00f3n Europea ha aprobado un\u00a0<\/span><strong style=\"color: #000000;font-family: Arial, sans-serif;font-size: 15px;text-align: justify\">medicamento destinado a retrasar la progresi\u00f3n de la diabetes tipo 1 en personas adultas y pedi\u00e1tricas a partir de los ocho a\u00f1os<\/strong><span style=\"color: #000000;font-family: Arial, sans-serif;font-size: 15px;text-align: justify\">. La autorizaci\u00f3n se produce tras el s\u00ed de la Agencia Europea de Medicamentos y convierte a teplizumab en la primera terapia modificadora del curso de la diabetes tipo 1 aprobada en la Uni\u00f3n Europea.<\/span><\/p><p style=\"text-align: justify\"><span style=\"color: #000000;font-family: Arial, sans-serif\"><span style=\"font-size: 15px\">Ver nota de prensa de FEDE (Federaci\u00f3n Nacional de Diabetes) en el siguiente bot\u00f3n<\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2233c1f e-con-full e-flex e-con e-parent\" data-id=\"2233c1f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7394b19 elementor-widget elementor-widget-button\" data-id=\"7394b19\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.fedesp.es\/portal\/actualidad\/?sec=europa-aprueba-un-innovador-tratamiento-para-la-dt1\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Nota de prensa FEDE<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>La Comisi\u00f3n Europea ha aprobado un\u00a0medicamento destinado a retrasar la progresi\u00f3n de la diabetes tipo 1 en personas adultas y pedi\u00e1tricas a partir de los ocho a\u00f1os. La autorizaci\u00f3n se produce tras el s\u00ed de la Agencia Europea de Medicamentos y convierte a teplizumab en la primera terapia modificadora del curso de la diabetes tipo [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-1435","post","type-post","status-publish","format-standard","hentry","category-hablemos-de-diabetes"],"_links":{"self":[{"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/posts\/1435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/comments?post=1435"}],"version-history":[{"count":5,"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/posts\/1435\/revisions"}],"predecessor-version":[{"id":1440,"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/posts\/1435\/revisions\/1440"}],"wp:attachment":[{"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/media?parent=1435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/categories?post=1435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adile.es\/index.php\/wp-json\/wp\/v2\/tags?post=1435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}